Ulcerative Colitis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeuti

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ulcerative Colitis pipeline constitutes 110+ key companies continuously working towards developing 110f+ Ulcerative Colitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ulcerative Colitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ulcerative Colitis Market.

The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ulcerative Colitis Pipeline Report: https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ulcerative Colitis treatment therapies with a considerable amount of success over the years.
• Ulcerative Colitis companies working in the treatment market are NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others, are developing therapies for the Ulcerative Colitis treatment
• Emerging Ulcerative Colitis therapies in the different phases of clinical trials are- MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others are expected to have a significant impact on the Ulcerative Colitis market in the coming years.
• In July 2023, the Phase 3 Step-Up HS study, which is evaluating upadacitinib (RINVOQ®) in adults and children with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy, has dosed its first patient, according to AbbVie (NYSE: ABBV).
• In June 2023, The novel medication mirikizumab, which Amsterdam UMC and collaborators from around the world are researching, is successful in treating ulcerative colitis. The clinical experiment showed that in some groups, the rates of remission doubled, reaching up to 50%
• In June 2023, The first patients in a Phase I clinical study of MAP 315, a live biotherapeutic product being developed for the treatment of ulcerative colitis (UC), were dosed by Microba Life Sciences
• In November 2021, For individuals with moderate to severe active left-sided ulcerative colitis, InDex Pharmaceuticals started a randomised double-blind placebo-controlled Phase III clinical research to assess the efficacy and safety of cobitolimod as an induction and maintenance medication
• In March 2020, In order to evaluate the safety of brazikumab in patients with moderately to severely active ulcerative colitis, AstraZeneca started a Phase II open-label, long-term extension safety trial.

Ulcerative Colitis Overview
Chronic large intestine condition called ulcerative colitis causes the colon's lining to become inflamed and form microscopic ulcers or opensores. Abdominal pain is brought on by the pus and mucus such ulcers create. Typically, it starts in the rectm and moves upward.

Get a Free Sample PDF Report to know more about Ulcerative Colitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Ulcerative Colitis Drugs Under Different Phases of Clinical Development Include:
• PRA023: Prometheus Biosciences
• OSE-127: OSE Immunotherapeutics
• Brazikumab: AstraZeneca
• MORF-057: Morphic Therapeutic
• Risankizumab: AbbVie
• Cobitolimod: InDex Pharmaceuticals
• Etrasimod: Pfizer
• PL8177: Palatin Technologies, Inc
• Mirikizumab: Eli Lilly and Company
• Guselkumab: Janssen Research & Development, LLC
• Efavaleukin alfa: Amgen
• NX-13: Landos Biopharma Inc.
• Remestemcel-L: Mesoblast, Inc.
• Ozanimod: Bristol-Myers Squibb
• ABX464: Abivax S.A.
• VTX002: Oppilan Pharma Ltd
• AJM300: EA Pharma Co., Ltd.
• PRA023 IV: Prometheus Biosciences, Inc.
• SAR443122: Sanofi
• GLPG3970: Galapagos NV
• Ozanimod: Celgene

Ulcerative Colitis Route of Administration
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Ulcerative Colitis Molecule Type
Ulcerative Colitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Ulcerative Colitis Pipeline Therapeutics Assessment
• Ulcerative Colitis Assessment by Product Type
• Ulcerative Colitis By Stage and Product Type
• Ulcerative Colitis Assessment by Route of Administration
• Ulcerative Colitis By Stage and Route of Administration
• Ulcerative Colitis Assessment by Molecule Type
• Ulcerative Colitis by Stage and Molecule Type

DelveInsight's Ulcerative Colitis Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ulcerative Colitis product details are provided in the report. Download the Ulcerative Colitis pipeline report to learn more about the emerging Ulcerative Colitis therapies at:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Ulcerative Colitis Therapeutics Market include:
Key companies developing therapies for Ulcerative Colitis are - Merck & Co., Inc.,, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Eli Lilly and Company, AbbVie Inc. (Allergan, Inc.), Bausch Health Companies Inc., Johnson and Johnson, Novartis AG, Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., and others.

Ulcerative Colitis Pipeline Analysis:
The Ulcerative Colitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
• Ulcerative Colitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ulcerative Colitis drugs and therapies-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Pipeline Market Drivers
• Increasing awareness and R&D investment, emergence of large number of novel pipeline molecules with great market potential are some of the important factors that are fueling the Ulcerative Colitis Market.

Ulcerative Colitis Pipeline Market Barriers
• However, side effects associated with the treatment, high cost treatment and other factors are creating obstacles in the Ulcerative Colitis Market growth.

Scope of Ulcerative Colitis Pipeline Drug Insight
• Coverage: Global
• Key Ulcerative Colitis Companies: NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others
• Key Ulcerative Colitis Therapies: MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers

Request for Sample PDF Report for Ulcerative Colitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ulcerative Colitis Report Introduction
2. Ulcerative Colitis Executive Summary
3. Ulcerative Colitis Overview
4. Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment
5. Ulcerative Colitis Pipeline Therapeutics
6. Ulcerative Colitis Late Stage Products (Phase II/III)
7. Ulcerative Colitis Mid Stage Products (Phase II)
8. Ulcerative Colitis Early Stage Products (Phase I)
9. Ulcerative Colitis Preclinical Stage Products
10. Ulcerative Colitis Therapeutics Assessment
11. Ulcerative Colitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ulcerative Colitis Key Companies
14. Ulcerative Colitis Key Products
15. Ulcerative Colitis Unmet Needs
16 . Ulcerative Colitis Market Drivers and Barriers
17. Ulcerative Colitis Future Perspectives and Conclusion
18. Ulcerative Colitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Ulcerative Colitis Market https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ulcerative Colitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Ulcerative Colitis Epidemiology https://www.delveinsight.com/report-store/ulcerative-colitis-uc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ulcerative Colitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.